<DOC>
	<DOCNO>NCT01245790</DOCNO>
	<brief_summary>A 2 stage study evaluate amount fostamatinib blood urine subject impair kidney ( renal ) function compare healthy volunteer normal renal function . Stage 1 include healthy subject subject end stage renal disease , Stage , 2 may include subject mild , moderate and/or severe renal impairment dependent outcome Stage 1 . The study also evaluate safety tolerability subject renal impairment .</brief_summary>
	<brief_title>A Study Fostamatinib Subjects With Impaired Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Males female ( non child bear potential ) great equal 18 year age suitable vein cannulation repeat venipuncture weight least 50 kg ( 110 lb ) body mass index ( BMI ) 18 40 kg/m2 , inclusive Stable renal impairment follow creatinine clearance ( CLCR ) : Stage 1 End Stage Renal Disease ( ESRD ) &lt; 15 mL/min ( require dialysis ) ; Stage 2 Mild renal impairment ≥ 50 &lt; 80 mL/min ; Moderate renal impairment ≥ 30 &lt; 50 mL/min ; severe renal impairment 15 &lt; 30 mL/min Healthy subject normal renal function must good health base medical history , physical examination , echocardiogram clinical laboratory evaluation include creatinine clearance &gt; 80 ml/min '' Negative screen Human Immunodeficiency Virus negative result serum hepatitis B surface antigen hepatitis C antibody Subjects receive medication know chronically alter drug absorption elimination process within 30 day first dose administration Absolute neutrophil count less 1600/mm3 1.6 x 109 L. Healthy subject : Subjects receive prescribed systemic topical medication within 14 day first dose administration Subjects history multiple drug allergy know allergy drug class fostamatinib In opinion Investigator , evidence additional severe uncontrolled systemic disease ( eg , currently unstable uncompensated hepatic , cardiovascular , respiratory disease ) laboratory find</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>volunteer renal impairment</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>fostamatinib</keyword>
	<keyword>Patients</keyword>
</DOC>